Nevirapine Conference Data

Medical Advocates
Nevirapine (Viramune)

Conference Citations

9th Int. Workshop on Clinical Pharmacology of HIV Therapy
15th CROI
4th IAS Conference
14th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI
Archived Conference Citations

NVP Main Page

Main New/Newsworthy

Home Page

Last Update: May 20, 2008
* Perinatal data are the Perinatal Data Page
** Pediatric data are in the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

9th Int. Workshop on Clinical Pharmacology of HIV Therapy

CONFERENCE PDF PRESENTATION
Total and unbound nevirapine pharmacokinetics in HIV-infected children treated with divided fixed-dose
combination tablets in Malawi.
Else LJ, Pollock L, Poerkson G, et al
Presentation

CONFERENCE PDF PRESENTATION
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication.
Stoehr W, Back D, Dunn D, et al
Presentation

15th Conference on Retroviruses and
Opportunistic Infections

Identification of Nevirapine-resistant HIV-1 in the Latent Reservoir following Single-dose Nevirapine
M Wind-Rotolo, C Durand, L Cranmer, et al
Abstract

POSTER
Risks Associated with Nevirapine Use in Pregnant and Non-pregnant Women
E Aaro, M Kempf, S Criniti, et al
PDF Poster Abstract

Low Hepatoxicity in Patients Randomized to Switching to Nevirapine Once Daily vs Continuing
with Nevirapine Twice Daily
D Podzamczer, M Olmo, J Sanz, et al
Abstract

Dynamics of Nevirapine-resistant HIV-1 following Single-dose NVP Assessed in Plasma and
Cells by Consensus Sequencing and Oligonucleotide Ligation Assay
C Kress, T Wagner N Ngo-Giang-Huong, et al
Abstract

Mechanism by which N348I in HIV-1 Reverse Transcriptase Confers Dual Zidovudine/Nevirapine
Resistance
Cremer, G Tachedjian
Abstract

NNRTI, Efavirenz and Nevirapine, Induce Leukocyte-Endothelial Cell Interactions in the
Microvasculature
M Andrade, F Baixauli, A Blas-Garcia, et al
Abstract

Pharmacokinetics of Nevirapine and Rifampicin in TB/HIV Co-infected Patients in Burkina Faso
A Matteelli, N Saleri, M Regazzi, et al
Abstract

Effectiveness of NNRTI-containing ART in Women Previously Exposed to a Single Dose of
Nevirapine: A Multi-country Cohort Study
P Weidle, J Stringer, M McConnell, et al
Abstract

Nevirapine Administered Once Daily Is as Efficient as a Twice-daily Dosing. A Collaborative
Cohort Study
A Calmy, A Nguyen, J Lange, et al
Abstract

POSTER
Nevirapine Pharmacokinetics in Thai Children Receiving either an Adult or Pediatric Fixed-dose |
Combination of Stavudine, Lamivudine, and Nevirapine
K Chokephaibulkit, T Cressey, W Prasitsuebsai, et al
PDF Poster Abstract

POSTER
Nevirapine Exposure with WHO Pediatric Weight Band Dosing--Enhanced Therapeutic Concentrations
Predicted Based on Extensive International Pharmacokinetic Experience
E Capparelli, D Kabamba, T Cressey, D Burger
PDF Poster Abstract

POSTER
Comparison of Adverse Fetal Outcomes in HIV-1-infected Antiretroviral-na�ve Pregnant Women
Who Have Received Combivir and Either Nevirapine or Nelfinavir for Prevention of Mother-to-Child
Transmission Antenatally
R Masaba, R Ndivo, I Nyangau, et al
PDF Poster Abstract

POSTER
Low Birth Weight with Nevirapine-based ART in Abidjan, C�te d�Ivoire: The ANRS Ditrame Plus
Cohort and MTCT-Plus Initiative, 2001 to 2007
DK Ekouevi, B Tonwe-Gold, R Becquet, et al
PDF Poster Abstract

POSTER
Intrapartum Tenofovir and Emtricitabine Reduces Development of Low-level NNRTI Resistance
following Ingestion of Single-dose Nevirapine for Perinatal HIV Prevention
B Chi, L Frenkel, G Aldrovandi, et al
PDF Poster

Abstract

POSTER
Emergence and Fading of Nevirapine Resistance after First versus Repeated Use of Single-dose
Nevirapine for Prevention of Mother-to-Child HIV Transmission: Women and Infants in the Repeat
Pregnancy Study in Uganda
S Eshleman T Flys, M McConnell
PDF Poster

Abstract

POSTER
Risks Associated with Nevirapine Use in Pregnant and Non-pregnant Women
E Aaro, M Kempf, S Criniti, et al
PDF Poster Abstract

POSTER
Analysis of NVP Resistance in Ugandan Infants Who Were HIV-infected despite Receiving
Single-dose Nevirapine vs Single-dose NVP Plus up to 6 Weeks of Daily NVP to Prevent HIV
Vertical Transmission
J Church, S Omer, L Guay, et al
PDF Poster Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Three-year extended follow-up of the 2NN study: a randomised comparative trial of first-line
antiretroviral therapy with regimens containing either nevirapine, efavirenz or both drugs
combined, together with stavudine and lamivudine
Wit F, Phanuphak P, Ruxrungtham K, et al
Abstract

Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell
counts in resource-limited setting
Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, et al
Abstract
24-week efficacy and safety of nevirapine: 400 mg versus 600 mg based HAART in HIV-infected
patients with active tuberculosis receiving rifampicin
Manosuthi W, Avihingsanon A, Kantipong P, et al
Abstract
Incidence of nevirapine-associated hypersensitivity reactions is different in patients with
prior treatment experience compared to treatment-na�ve patients: the ATHENA cohort study
Wit F, Kesselring A, Gras L, et al
Abstract

Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN-g responses in PBMC
from HIV-infected patients with abacavir or nevirapine hypersensitivity reactions
Keane N, Lucas A, Netto J, et al
Abstract
History of drug allergy associated with nevirapine toxicity among AIDS patients with low
baseline CD4 count
Maek-a-nantawat W, Tansuphaswadikul S, Eindani Aung S, et al
Abstract

XVI International AIDS Conference

Nevirapine is detectable in breast milk up to 2 weeks after single dose
A. Kunz, K. Mugenyi, H. Karcher, et al
Abstract

An indication of nevirapine (012 regime) failure in a programme setting in Malawi
G. Kamanga, C. Zimba
Abstract

Pharmacokinetic interaction between itraconazole and nevirapine in healthy volunteers
S. Jaruratanasirikul, S. Sriwiriyajan
Abstract

Effectiveness of nevirapine in reducing mother to child transmission of HIV in a non clinical trial setting,
Zimbabwe, 2005
A. Muchedzi, M. Tshimanga, D. Jones, et al
Abstract

Injectable sustained release nevirapine, designed to be co-administered in programs of
accelerated DPT immunization, for the prevention of mother-to-child HIV transmission associated
with breast feeding
T. Smith, J.L. Sullivan, M. Neely, et al
Abstract

Long term efficacy and tolerability of nevirapine based first-line regimens in HIV-1-infected adults
L. Cuzin, M. Biboulet, P. Pugliese, et al
Abstract

Incidence and characteristics of Nevirapine - related rash among HIV-infected patients with severe
immunosupression and initial full-dose Nevirapine
J. Claros, J.A. Collins, C. Rojas
Abstract

HAART with initial full-dose Nevirapine is not associated with higher risk of rash among HIV
patients with severe immunosupression
J.A. Collins, J. Claros, L. Hercilla
Abstract

Mucosal exposure to HIV-1 does not lead to intrapartum transmission after nevirapine single dose
A. Kunz, K. Mugenyi, H. Karcher, et al
Abstract

Clonal analysis of the diversity in drug resistant subtype C HIV-1 after single dose nevirapine
S. Kassaye, E. Lee, B. Johnston, et al
Abstract

Nevirapine concentrations in HIV-infected children treated with divided fixed dose combination
tablets in Malawi and Zambia
V. Mulenga, J. Ellis, F. Ewings, et al
Abstract

Cost of multi-dose antiretroviral (ARV) versus single-dose nevirapine treatment for prevention of
mother-to-child HIV transmission (pMTCT) in the Dominican Republic (DR): potential savings
associated with greater efficacy
J. Roman-Pouriet, N. Kley, A.D. Fernandez, et al
Abstract

Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of Nevirapine
tablets in 18 healthy volunteers
E. Mahler, D. Fridman, C. Monz�n, et al
Abstract

Effectiveness of single dose nevirapine or azt in preventing HIV transmission from mother to child
R. Navuga, R. Kizito, A. Nalubowa, et al
Abstract

Immune restoration syndrome (IRS) as a surrogate marker for immunologic response to generic,
nevirapine-based V.S. to efavirenz- based antiretroviral regimens
O. Putcharoen, C. Suankratay, T. Tantawichien, et al
Abstract

Resistance induced by the use of single dose nevirapine (sdNVP) for prevention of mother-to-child
transmission of HIV (PMTCT): debate and reality, experience in Nigeria
J. Mandala, A. Abutu, L. Anomnachi, et al
Abstract

Can routine alanine transaminase (ALT) monitoring be simplified in patients starting a nevirapine
containing antiretroviral treatment regimen? An experience from a clinic setting in Maputo, Mozambique
S. Mikusova, M. Biot, R. Bastos, et al
Abstract

Hepatotoxicity in injection drug users (IDUs) and non-IDUs receiving nevirapine-based HAART
H. Tossonian, J. Raffa, J. Grebely, et al
Abstract

Virological and immunological response after naive HIV-infected patients who received
nevirapine -based antiretroviral Therapy
N. Chumpathat, S. Likanonsakul, B. Kowadisaiburana, et al
Abstract

Immunological and virological response after naive HIV-infected patients who received nevirapine-based
antiretroviral therapy
N. Chumpathat, S. Likanonskul, B. Kovadisaiburana, et al
Abstract

Generic fixed-dose combination of nevirapine, stavudine, and lamivudine: 2-year assessment in Cameroon
S. Koulla-Shiro, C. Laurent, C. Kouanfack, et al
Abstract

Incidence of rash and severe hepatotoxicity in patients switching from a protease inhibitor (PI) or
efavirenz (EFV) to nevirapine (NVP) at relatively high CD4 count levels
A. De Roo, F. Moerman, L. Lynen, et al
Abstract

Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced patients
with high and low CD4 counts
A. Mocroft, K. Lacombe, J. Rockstroh, et al
Abstract

Challenges of nevirapine toxicity at the antiretroviral centre in Jos, Nigeria
G. Onwuegbuzie, O. Agbaji, T. Babafemi, et al
Abstract

Efficacy and safety of nevirapine versus efavirenz when combined in ART regimens in HIV-infected
antiretroviral-na�ve persons (the NNRTI substudy of FIRST-CPCRA 058)
M. van den Berg-Wolf, G. Peng, Y. Xiang, et al
Abstract

Nevirapine-associated hepatic toxicity among HIV-1-seropositive pregnant women in Mozambique
L. Jamisse, J. Balkus, J. Hitti, et al
Abstract

Maternal immune response and clinical outcomes on NNRTI-based antiretroviral therapy (ART) following
exposure to single-dose nevirapine (NVP) for prevention of mother-to-child HIV transmission (PMTCT)
B. Chi, M. Sinkala, J. Levy, et al
Abstract

Morbidity profiles among patients on generic nevirapine, zidovudine and lamivudine for the treatment of
AIDS in a resource-limited setting
L. Zijenah, G. Kadzirange, N. Gonah, et al
Abstract

Elimination kinetics of single 200 mg dose of oral nevirapine in HIV-1-infected pregnant Indian women
R.B. Mhatre, P.A. Thakur, S. Dalvi, et al
Abstract

Incidence and predictors of hepatotoxicity among patients receiving nevirapine (NVP)-containing
antiretroviral therapy (ART) in Zambia
R. Cantrell, B. Chi, L. Mulenga, et al
Abstract

Efficacy and tolerability of nevirapine-based regimen VS efavirenz-based regimen in HIV-infected
Thai children
K. Lapphra, N. Vanprapar, S. Chearskul, et al
Abstract

Analysis of hepatic events after nevirapine containing regimens in the real life by CD4+, gender and
HCV co-infection. Results from a single centre study
C. Torti, G. Lapadula, M. Puoti, et al
Abstract

24 month outcome of nevirapine based highly active antiretroviral therapy (HAART) in women during
the postpartum period: a PMTCT+ pilot program supported by the Global Fund in Thailand
G. Jourdain, N. Briand, F. Fregonese, et al
Abstract

Adverse reactions related to antiretroviral regimen containing nevirapine used by HIV-infected
pregnant women from the maternal and perinatal cohort of Belo Horizonte, Brazil
R.A.L.P. Aguiar, V.H. Melo, I.K.D.Cavallo, et al
Abstract

Toxicity of nevirapine in HIV-infected women with high CD4 counts in Malawi: the BAN study
B. Bramson, C. Chasela, C. Chavula, et al
Abstract

How to target TOPS: Combivir to reduce nevirapine-resistance after PMTCT: a stochastic model
D. Westreich, A. Van Rie
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Protease inhibitor-based antiretroviral therapy switch to efavirenz-based regimens
P Khaykin, S Staszewski, B Dauer, et al
Abstract

Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large
cohort of antiretroviral-na�ve patients with advanced HIV infection
F Pulido, J Arribas, S Moreno, et al
Abstract

Efavirenz (EFV) vs. Lopinavit/ritonavir (LPV/r)-based combined antiretroviral therapy in antiretroviral-nave
HIV-infected patients from the Spanish VACH cohort: the SUSKA study
P Domingo, R Teira, I Suarez-Lozano, et al
Abstract
Simplification from protease inhibitor (PI) to efavirenz (EFV) based HAART in virologically suppressed
HIV-infected subjects
CCohen, E DeJesus, R Campo, et al
Abstract
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with
abacavir/lamivudine (Kivexa), in naive patients: a multicentre, randomized study
P Echeverria, G Carosi, J Galves, et al
Abstract
High efavirenz trough concentrations (ETC) and CNS toxicity are associated with CYP2B6
single nucleotide polymorphisms (SNPs) in black Africans
S Andrews, S Fredericks, Y Jamshdi, et al
Abstract
TDM of efavirenz as a tool of adherence in HIV-infected children
R Rosso, A Di Biagio, C Dentone, et al
Abstract

Simplification to efavirenz + abacavir/lamivudine (Kivexa) in previously suppressed HIV-infected
patients compared with other conventional regimens of 2 nucleosides + efavirenz: 6-months of follow-up
P Echeverria, J de la Torre, J Pasquau, et al
Abstract

Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz
concentrations
L Else, L Dickinson, M Schellenberger, et al
Abstract

14th Conference on Retroviruses and
Opportunistic Infections

Detection of Drug Resistance by Population Sequencing and Allele Specific PCR for K103N after
Nevirapine-based HAART in Subtype C HIV-1 in Zimbabwe
J Ledwaba, V Pillay, S Dalai, et al
Abstract
Superior Virological Suppression with Nevirapine, Zidovudine, and Lamivudine vs Abacavir, Zidovudine,
and Lamivudine without Evidence of Clinical Benefit to 48 Weeks: A Randomized Comparison in
Patients with Low CD4 Counts in Africa
S Walker, C Kityo, P Kaleebu, et al
Abstract
Influence of CYP2B6 Polymorphism on Plasma Concentrations of Efavirenz and Nevirapine in
HIV-infected Patients in South India
G Ramachandran, I Jagan, K Ramesh, et al
Abstract
Pharmacokinetics and 12 Weeks Efficacy of Nevirapine, 400 mg vs 600 mg per day in
HIV-infected Patients with Active TB Receiving Rifampicin: A Multicenter Study
A Avihingsanon, W Manosuthi, P Kantipong, et al
Abstract
Addition of Short-course Combivir to Single-dose Nevirapine Reduces the Selection of
NPV-resistant HIV-1 with Infrequent Emergence of 3TC-resistant Variants
S Palmer, V Boltz, F Maldarelli, et al
Abstract
POSTER
A Novel Mutation, N348I in HIV-1 Reverse Transcriptase Induced by NRTI Treatment, Confers
Nevirapine Resistance
A Hachiya, E Kodama, S Sarafianos, et al
PDF Poster Abstract

POSTER
A Mutation in the Connection Subdomain of the HIV-1 Reverse Transcriptase (N348I) Is Selected
Commonly in vivo and Confers Decreased Susceptibility to Zidovudine and Nevirapine
SH Yap, B Wynhoven, M Kuiper, et al
PDF Poster Abstract

POSTER
Pharmacokinetics of Nevirapine, Stavudine, and Lamivudine in HIV-infected Children in Zambia
Treated with Pediatric Fixed-dose Combination Tablets
D Kabamba, R L'homme, F Ewings, et al
PDF Poster Abstract

13th Conference on Retroviruses and
Opportunistic Infections

Effect of Rifampin Hepatic Induction on Nevirapine Levels in Indian Volunteers